Several non-clinical and clinical studies support the combination of PAM inhibitors and CDK4/6 inhibitors in tumors other than breast cancer, based on the rationale that these two pathways can compensate for each other when these inhibitors are used as single agents [46,47,48]. This evidence concerns the gene CDK4 and breast carcinoma.